Evidence map›Paper›PMID 31399108›Full record

ArticleRadiation oncology (London, England)2019

Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity.

Jérôme Lacombe, Muriel Brengues, Alain Mangé, Céline Bourgier, Sophie Gourgou, André Pèlegrin, Mahmut Ozsahin, Jérôme Solassol, David Azria

Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00893035 (Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00893035 completednot on this map

Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.

TypeobservationalSponsorInstitut du Cancer de Montpellier - Val d'AurelleRan2006 to 2019Enrolled885ConditionsBreast Cancer, Prostate Cancer
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. -Omics potential of in vitro skin models for radiation exposure.Cellular and molecular life sciences : CMLS · 2022
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jérôme LacombeIRCM, INSERM, University Montpellier, ICM, Montpellier, France.
Muriel BrenguesIRCM, INSERM, University Montpellier, ICM, Montpellier, France.
Alain MangéIRCM, INSERM, University Montpellier, ICM, Montpellier, France.
Céline BourgierIRCM, INSERM, University Montpellier, ICM, Montpellier, France.
Sophie GourgouICM, Institut Cancer Montpellier, Montpellier, France.
André PèlegrinIRCM, INSERM, University Montpellier, ICM, Montpellier, France.
Mahmut OzsahinCHU Vaudois, Lausanne, Switzerland.
Jérôme SolassolIRCM, INSERM, University Montpellier, ICM, Montpellier, France.
David AzriaIRCM, INSERM, University Montpellier, ICM, Montpellier, France. david.azria@icm.unicancer.fr.ORCID http://orcid.org/0000-0002-7533-2988
Inserm · FRCEA Valduc · FRUniversity Hospital of Lausanne · CH

Funding

Institut National Du Cancer INCa-DGOS-Inserm 6045
6 · The paper itself

Abstract

backgroundBiomarkers for predicting late normal tissue toxicity to radiotherapy are necessary to personalize treatments and to optimize clinical benefit. Many radiogenomic studies have been published on this topic. Conversely, proteomics approaches are not much developed, despite their advantages.

methodsWe used the isobaric tags for relative and absolute quantitation (iTRAQ) proteomic approach to analyze differences in protein expression levels in ex-vivo irradiated (8 Gy) T lymphocytes from patients with grade ≥ 2 radiation-induced breast fibrosis (grade ≥ 2 bf+) and patients with grade < 2 bf + after curative intent radiotherapy. Patients were selected from two prospective clinical trials (COHORT and PHRC 2005) and were used as discovery and confirmation cohorts.

resultsAmong the 1979 quantified proteins, 23 fulfilled our stringent biological criteria. Immunoblotting analysis of four of these candidate proteins (adenylate kinase 2, AK2; annexin A1; heat shock cognate 71 kDa protein; and isocitrate dehydrogenase 2) confirmed AK2 overexpression in 8 Gy-irradiated T lymphocytes from patients with grade ≥ 2 bf + compared with patients with grade < 2 bf+. As these candidate proteins are involved in oxidative stress regulation, we also evaluated radiation-induced reactive oxygen species (ROS) production in peripheral blood mononuclear cells from patients with grade ≥ 2 bf + and grade < 2 bf+. Total ROS level, and especially superoxide anion level, increased upon ex-vivo 8 Gy-irradiation in all patients. Analysis of NADPH oxidases (NOXs), a major source of superoxide ion in the cell, showed a significant increase of NOX4 mRNA and protein levels after irradiation in both patient groups. Conversely, only NOX4 mRNA level was significantly different between groups (grade ≥ 2 bf + and grade < 2 bf+).

conclusionThese findings identify AK2 as a potential radiosensitivity candidate biomarker. Overall, our proteomic approach highlights the important role of oxidative stress in late radiation-induced toxicity, and paves the way for additional studies on NOXs and superoxide ion metabolism.

Indexed as

Adenylate KinaseBiomarkersBreastBreast NeoplasmsFemaleFibrosisHumansOrgans at RiskPrognosisProspective StudiesProteomeRadiation InjuriesRadiation ToleranceRadiotherapyReactive Oxygen SpeciesT-LymphocytesAdenylate Kinaseadenylate kinase 2BiomarkersProteomeReactive Oxygen SpeciesAK2NADPH oxidasesNormal tissue radiotoxicityProteomicsRadiation-induced breast fibrosisRadiosensitivityRadiotherapy

Identifiers

PMID31399108
PMCPMC6688300
OpenAlexW2968339581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.